- The disease
- Solid tumours is a broad category covering cancers that form discrete masses in organs or tissues, as distinct from blood cancers. Cabazitaxel is a chemotherapy agent that belongs to the taxane class, which works by interfering with cell division. It is approved by the US Food and Drug Administration (FDA) for certain prostate cancer indications (per FDA prescribing information for Jevtana). The specific tumour types targeted in this DEP cabazitaxel study are .
- What the asset is trying to do
- DEP cabazitaxel uses Starpharma's DEP (dendrimer-enhanced product) platform, which is a drug delivery technology based on dendrimer molecules -- highly branched synthetic structures designed to carry a drug payload. The intent of the DEP platform is to alter how the drug is distributed in the body, potentially increasing drug concentration at tumour sites and modifying the tolerability profile relative to conventional formulations. Specific pharmacokinetic or pharmacodynamic data for DEP cabazitaxel in this study are .
- What the trial is measuring, and why it matters
- The endpoints being measured in this Phase 2 study are . In oncology trials at this stage, primary endpoints commonly include measures of tumour response or safety, while secondary endpoints may include duration of response or progression-free survival; however, the specific endpoints for this trial have not been confirmed from available data. Confirmation of endpoints should be drawn from the trial registry record once the NCT identifier is available.
- Efficacy benchmarks in this setting
- In the approved setting for cabazitaxel (metastatic castration-resistant prostate cancer previously treated with docetaxel), the TROPIC trial reported a median overall survival of 15.1 months for cabazitaxel versus 12.7 months for mitoxantrone (de Bono et al, Lancet 2010). For solid tumour indications more broadly, approved taxane-based regimens achieve objective response rates and survival outcomes that vary widely by tumour type and line of therapy; specific benchmarks for the tumour types enrolled in this DEP cabazitaxel study are . Any early-stage figures reported for DEP cabazitaxel are not statistically comparable to results from large randomised trials of approved agents.
- Commercial context
- Cabazitaxel (brand name Jevtana) is approved by the FDA for metastatic castration-resistant prostate cancer (per FDA prescribing information for Jevtana); its approval status in other solid tumour indications is . DEP cabazitaxel is one of several assets in Starpharma's DEP oncology pipeline, which also includes DEP HER2, for which Starpharma announced in April 2026 that the FDA confirmed a path to a first-in-human study (per ASX announcement 20 April 2026). No licensing deals or manufacturing partnerships specific to DEP cabazitaxel have been disclosed in the available data.